34 I-7-6-1) Mécanismes moléculaires impliqués dans le phénomène d'hormonorésistance, p.35 ,
46 II-1-2-3-1) Mécanisme d'action du vaccin 47 II-1-2-3-2) Essais cliniques, 48 II-1-2-3-3) PROSTVAC en combinaison avec les thérapies standards, p.49 ,
55 II-2-1) acétate d'abiraterone (ZYTIGA®) 55 II-2-1-1) Population cible 56 II-2-1-2) 56 II-2-1-3) Essais cliniques 57 II-2-1-4) Effets indésirables, pp.58-60 ,
74 II-4-5-1) Rôle des clusterines dans le cancer de la prostate 74 II-4-5-2) Cibler les clusterines avec une technologie, p.76 ,
77 II-5-1) Le denosumab : un anticorps monoclonal anti-ostéoclastique 78 II-5-1-1) Mécanisme d'action, p.78 ,
79 II-5-2-1) Posologie mode d'administration, p.82 ,
82 II-6-1) Options thérapeutiques chez les patients chimio naïfs, pp.82-88 ,
La prostate : une glande au carrefour uro-g??nital, Progr??s en Urologie, vol.22, pp.2-6, 2012. ,
DOI : 10.1016/S1166-7087(12)70028-3
Androgen receptor signaling in prostate cancer development and progression, J Carcinog aout, vol.10, issue.20, pp.22-41, 2011. ,
Cancer de la prostate -Identification des facteurs de risque et pertinence d'un dépistage par dosage de l'antigène spécifique prostatique (PSA) de population d'hommes à haut risque?, Février, 2012. ,
Disponible sur: http://scd.uhp-nancy.fr/docnum/SCDPHA_T_2009_POIRIER_JOSEPHINE.pdf 10. Boissier R. L'antigène spécifique de la prostate ou PSA, Prog Urol, vol.21, issue.11, pp.798-800, 2009. ,
Antigène spécifique de la prostate (PSA) : dosage en connaissance de cause, Forum Med Suisse, vol.9, pp.28-37, 2009. ,
Guidelines on prostate cancer, 2014. ,
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease, JAMA, vol.279, issue.19, pp.1542-1549, 1998. ,
DOI : 10.1001/jama.279.19.1542
CUA guidelines on prostate biopsy methodology, Canadian Urological Association Journal, vol.4, issue.2, pp.89-94, 2010. ,
DOI : 10.5489/cuaj.797
URL : http://europepmc.org/articles/pmc2845759?pdf=render
État de l'art: antibioprophylaxie pour les biopsies de prostate: State of art: antibioprophylaxis for biopsy of the prostate, Prog Urol, vol.18, issue.3, pp.15-18, 2008. ,
Disponible sur: http://www.urofrance.org/nc/lurologiegrandpublic/fiches-patient/resultats-de-la-recherche/html/biopsie-echoguidee-de-laprostate .html 17. Ploussard G, de la Taille A. Test urinaire PCA3 en pratique clinique, Prog Urol, vol.19, issue.3, pp.86-901, 2008. ,
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer, European Urology, vol.44, issue.1, pp.8-15, 2003. ,
DOI : 10.1016/S0302-2838(03)00201-X
DD3 RNA Analysis in Urine ? A New Perspective for Detecting Prostate Cancer, European Urology, vol.46, issue.2, pp.182-188, 2004. ,
DOI : 10.1016/j.eururo.2004.06.004
uPM3, a new molecular urine test for the detection of prostate cancer, Urology, vol.64, issue.2, pp.311-316, 2004. ,
DOI : 10.1016/j.urology.2004.03.052
The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance, Clinical Cancer Research, vol.13, issue.3, pp.939-982, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2679
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome, The Journal of Urology, vol.179, issue.4, pp.1587-92, 2008. ,
DOI : 10.1016/j.juro.2007.11.038
Test urinaire PCA3 en pratique clinique, Progr??s en Urologie - FMC, vol.19, issue.3, pp.86-90, 2009. ,
DOI : 10.1016/j.fpurol.2009.06.001
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results, The Prostate, vol.17, issue.11, pp.1215-1237, 2008. ,
DOI : 10.1002/pros.20781
G??nes de fusion et cancer de la prostate. De la d??couverte ?? la valeur pronostique et aux perspectives th??rapeutiques, Progr??s en Urologie, vol.19, issue.11, pp.819-843, 2009. ,
DOI : 10.1016/j.purol.2009.06.002
Biomarqueurs urinaires du cancer de prostate, Progr??s en Urologie, vol.20, issue.13, pp.1184-91, 2010. ,
DOI : 10.1016/j.purol.2010.07.017
D??tection combin??e des g??nes de fusion TMPRSS2-ERG dans l???urine et le liquide de rin??age du pistolet ?? biopsies de la prostate, Progr??s en Urologie, vol.23, issue.13, pp.1041-1043, 2013. ,
DOI : 10.1016/j.purol.2013.08.057
Le score de Gleason pour les nuls, Progr??s en Urologie - FMC, vol.24, issue.1, pp.13-15, 2014. ,
DOI : 10.1016/j.fpurol.2013.06.004
Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate, Progrès en Urologie, vol.23, pp.67-101, 2013. ,
Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate, Prog Urol, vol.23, pp.67-101, 2013. ,
Place de la surveillance active dans le cancer de la prostate: présentation du protocole français: Active surveillance in prostate cancer: the French protocol, Prog Urol, vol.18, issue.4, pp.12-16, 2008. ,
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer, JAMA, vol.293, issue.17, pp.2095-101, 2005. ,
DOI : 10.1001/jama.293.17.2095
Détection précoce du cancer de la prostate : actualisation du référentiel de pratiques de l'examen périodique de santé (EPS). [cité 17, 2014. ,
has-sante.fr/portail/upload/docs/application/pdf/2013- 07/referentieleps_format2clic_kc_prostate_vfinale.pdf 36. Gross E. Radiothérapie conformationelle du cancer de prostate, Prog Urol, vol.21, issue.11, pp.801-808, 2011. ,
OBI, radiothérapie avec modulation d'intensité, imagerie portale ,
radiotherapie-lyon-macon.fr/lyon/equipements-oncologielyon .asp?idcat=2 38 ,
lurologie-grandpublic/fiches-patient/resultatsde-la-recherche/html/curietherapie-de-la-prostate .html?type=123 39. Association Francaise d'urologie. HIFU traitement du cancer de la prostate par ultrasons focalisés de haute intensité, 2012. ,
Le traitement hormonal du cancer de la prostate, Progr??s en Urologie, vol.23, issue.15 ,
DOI : 10.1016/j.purol.2013.08.325
Disponible sur: http://www.pharmacorama.com/Rubriques/Output/Hormones_antehypophysairesa3.ph p 42. FIRMAGON 80mg poudre pour solution injectable -Monographie spécialité. [cité 22 août 2014]. Base de données médicamenteuses Thériaque. Disponible sur: http://www.theriaque.org/apps/monographie/index.php?type=SP&id=25047 43, Disponible sur, 2014. ,
Quand est-ce que je propose un blocage androg??nique complet???, Progr??s en Urologie - FMC, vol.20, issue.1, pp.2-5, 2010. ,
DOI : 10.1016/j.fpurol.2009.09.003
Combined androgen blockade with bicalutamide for advanced prostate cancer, Cancer, vol.174, issue.15, pp.3437-3482, 2009. ,
DOI : 10.1002/cncr.24395
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer, International Journal of Molecular Sciences, vol.73, issue.03_MeetingAbstracts, pp.13958-78, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-3630
Pathophysiology of bone metastases and new molecular targets involved in bone remodelling, Bulletin du Cancer. nov, vol.100, issue.11, pp.1083-91, 2013. ,
Physiopathology of bone metastases, Oncologie, vol.11, issue.1, pp.10-15, 2009. ,
DOI : 10.1007/s10269-008-0977-1
Biologie mol??culaire de la prostate??normale et pathologique, EMC - Urologie, vol.4, issue.2, pp.1-10, 2011. ,
DOI : 10.1016/S1762-0953(11)46413-X
Le concept d'hormonorésistance revisité dans le cancer de la prostate métastatique: implications thérapeutiques, Prog Urol, vol.14, pp.1119-1143, 2004. ,
Mécanisme moléculaire du cancer de la prostate hormonorésistant Disponible sur: http://urologie-chumondor .aphp.fr/_recherche/tu_prost/mec_mol_echapp.htm 55 Guidelines on prostate Cancer. Part II : treatment of advanced, relapsing, and castration-resistant prostate cancer. European Association of urology, pp.572-83, 2011. ,
Prostate cancer vaccines, OncoImmunology, vol.53, issue.5, p.24523 ,
DOI : 10.1016/S0360-3016(01)01692-3
immunothérapie: une nouvelle approche dans La prise en charge du cancer de prostate résistant à la castration, Bulletin du cancer, vol.99, pp.57-65 ,
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines, Seminars in Oncology, vol.39, issue.3, pp.296-304, 2012. ,
DOI : 10.1053/j.seminoncol.2012.02.010
Disponible sur: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts, Approved Products/ucm210215.htm 60. Provenge, Autologous peripheral blood mononuclear cells activated with PAP-GM- CSF (Sipuleucel-T). [cité 16 mai 2014], 2010. ,
Emerging Roles of Human Prostatic Acid Phosphatase, Biomol Ther (Seoul). janv, vol.6221, issue.1, pp.10-20, 2013. ,
Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches, Journal of Clinical Oncology, vol.29, issue.27, pp.3677-85, 2011. ,
DOI : 10.1200/JCO.2010.34.5025
Suisse [cité 16 janv 2015] Disponible sur: http://www.hematologie.chuv.ch/hem_home/hemprofessionnels/hem-pro-transplantation/hem-lexique/hem-pro-leucapherese .htm 65. Ouzaid I, Ravery V. Sipuleucel-T: un vaccin contre le cancer de la prostate:«mode d'emploi» pour les urologues, Prog Urol, vol.21, issue.9, pp.595-603, 2011. ,
Prostate cancer as a model for tumour immunotherapy, Nature Reviews Immunology, vol.14, issue.8, pp.580-93, 2010. ,
DOI : 10.4049/jimmunol.171.4.2161
dendreon.com/prescribing-information.pdf 68 Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, Asian J Androl New England Journal of Medicine, vol.69363, issue.5, pp.411-433, 2010. ,
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1099-105, 2010. ,
DOI : 10.1200/JCO.2009.25.0597
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer, Expert Opinion on Investigational Drugs, vol.16, issue.7, pp.1001-1012, 2009. ,
DOI : 10.1158/1078-0432.CCR-07-5212
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer, Clinical Cancer Research, vol.11, issue.9, pp.3353-62, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2062
Mechanism of Synergy of Levamisole and Fluorouracil: Induction of Human Leukocyte Antigen Class I in a Colorectal Cancer Cell Line, JNCI Journal of the National Cancer Institute, vol.87, issue.7, pp.489-96, 1995. ,
DOI : 10.1093/jnci/87.7.489
Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity, Cancer Res. 1 nov, vol.58, issue.21, pp.4790-4793, 1998. ,
A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1260-1269, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2059
vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer, J Urol. août, vol.174, issue.2, pp.539-585, 2005. ,
T-cell regulation by CD28 and CTLA-4, Nature Reviews Immunology, vol.405, issue.3, pp.220-228, 2001. ,
DOI : 10.1038/35011091
Immune-Checkpoints : les nouvelles i mmunothérapies anticancéreuses YERVOY 5mg/mL solution injectable -Monographie spécialité, Base de données médicamenteuses Thériaque.Disponible sur, pp.601-611, 2013. ,
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer ClinicalTrials ,
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014, Journal of Translational Medicine, vol.49, issue.suppl 2, 2014. ,
DOI : 10.1073/pnas.1016569108
Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012. ,
DOI : 10.1056/NEJMoa1200690
Nivolumab (anit-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small-cell lung cancer : survival and clinical activity by subgroup analysis, Journal of Clinical Oncology, vol.32, issue.5, p.2014, 2015. ,
Nouvelles th??rapeutiques dans le cancer de la prostate r??sistant ?? la castration??: panorama des ??tudes pivotales et nouveaux sch??mas th??rapeutiques ?? venir, Progr??s en Urologie, vol.23, issue.1, pp.1-7, 2013. ,
DOI : 10.1016/j.purol.2012.07.007
Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration- Resistant Prostate Cancer and No Prior Chemotherapy, N Engl J Med, vol.368, issue.2, pp.2012-04138, 2013. ,
L'évaluation en oncologie : comment je fais en imagerie ? EM-Consulte, 2009. ,
DOI : 10.1016/s0181-9801(09)73601-2
Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011. ,
DOI : 10.1056/NEJMoa1014618
20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats, J Steroid Biochem Mol Biol. mars, vol.17134, pp.80-91, 2013. ,
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Design 97. Enzalutamide, modalités pratiques d'utilisation d'une nouvelle hormonothérapie .Management of enzalutamide, a new hormonal therapy, Disponible sur, 2013. ,
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone, European Urology, vol.65, issue.1, pp.30-36, 2014. ,
DOI : 10.1016/j.eururo.2013.06.042
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014. ,
DOI : 10.1056/NEJMoa1405095
Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects, Journal of Pharmacology and Pharmacotherapeutics, vol.4, issue.4, pp.230-237, 2013. ,
DOI : 10.4103/0976-500X.119704
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.15, issue.2, pp.723-753, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-0596
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer, Drug Des Devel Ther. 10 mars, vol.5, pp.117-141, 2011. ,
Angiogenesis in prostate cancer: onset, progression and imaging, BJU International, vol.45, issue.11c, pp.794-808, 2012. ,
DOI : 10.1097/RLI.0b013e3181ee8b83
Le mécanisme de l'angiogénèse tumorale, Prog Urol, vol.144, pp.1-5, 2007. ,
Angiogenesis and anti-angiogenic therapy in prostate cancer, J Carcinog, vol.10, 1920. ,
Angiogenesis as a strategic target for prostate cancer therapy, Medicinal Research Reviews, vol.18, issue.1, pp.23-66, 2010. ,
DOI : 10.1016/j.urolonc.2004.08.013
Mécanismes de résistance aux thérapeutiques moléculaires ciblées dans le cancer du sein: constats et perspectives, Bulletin du cancer, vol.97, issue.3, pp.385-95, 2010. ,
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401, Journal of Clinical Oncology, vol.30, issue.13, pp.1534-1574, 2012. ,
DOI : 10.1200/JCO.2011.39.4767
Re: Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial, The Journal of Urology. mars, vol.191, issue.3, pp.656-663, 2014. ,
Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma, Cancer Chemotherapy and Pharmacology, vol.19, issue.11, pp.219-241, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-0319
Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer, The Cancer Journal, vol.19, issue.1, pp.90-98, 2013. ,
DOI : 10.1097/PPO.0b013e318281e280
Elixis announce Results from the comet-1 phase 3 Pivotal Trail of cabozantinib in men with CRPC, 2014. ,
A review of tasquinimod in the treatment of advanced prostate cancer, Drug Des Devel Ther, vol.7, pp.167-74, 2013. ,
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer, OncoTargets and therapy. fevrier, vol.7, pp.223-257, 2014. ,
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer, British Journal of Cancer, vol.143, issue.8, pp.1233-1273, 2009. ,
DOI : 10.1056/NEJMoa040720
Tasquinimod: a novel drug in advanced prostate cancer, Future Oncology, vol.52, issue.9, pp.1271-81, 2013. ,
DOI : 10.1016/j.jchromb.2011.09.013
Clusterin: a key player in cancer chemoresistance and its inhibition, OncoTargets and Therapy, vol.447, 2014. ,
DOI : 10.2147/OTT.S58622
Potential use of custirsen to treat prostate cancer, OncoTargets and Therapy, vol.6, pp.785-97, 2013. ,
DOI : 10.2147/OTT.S33077
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014. ,
DOI : 10.4103/1008-682X.122591
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, The Lancet, vol.377, issue.9768, pp.813-835, 2011. ,
DOI : 10.1016/S0140-6736(10)62344-6
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, The Lancet, vol.379, issue.9810, pp.39-46, 2012. ,
DOI : 10.1016/S0140-6736(11)61226-9
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation | Cancer Network, Oncology Journal. 17 avr, 2012. ,
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013. ,
DOI : 10.1056/NEJMoa1213755
FDA approves new drug for advanced prostate cancer, Disponible sur, 2014. ,
Cancer de prostate résistant à la castration : quelle prise en charge en 2014 ? Progrès en Urologie -FMC, pp.73-82, 2014. ,
DOI : 10.1016/j.fpurol.2014.05.003
Dépistage du cancer de la prostate : les arguments « pour ». Annales d'urologie, pp.179-83, 2006. ,
Dépistage du cancer de la prostate : pourquoi, comment ? Revue du practicien, pp.469-79, 2013. ,
Dépistage du cancer de la prostate, Prog Urol, vol.209, 2003. ,
Dépistage du cancer de la prostate : les arguments « contre ». Annales d'Urologie, avr, vol.40, issue.2, pp.101-106, 2006. ,
DOI : 10.1016/j.mednuc.2007.11.005
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, The Lancet, vol.384, issue.9959, pp.2027-2062, 2014. ,
DOI : 10.1016/S0140-6736(14)60525-0
Mortality results from the G??teborg randomised population-based prostate-cancer screening trial, The Lancet Oncology, vol.11, issue.8, pp.725-757, 2010. ,
DOI : 10.1016/S1470-2045(10)70146-7
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer, New England Journal of Medicine, vol.370, issue.10, pp.932-974, 2014. ,
DOI : 10.1056/NEJMoa1311593
Dépistage du cancer de la prostate : utilité, buts et perspectives en 2010, Urologie. 8 déc, vol.274, issue.44, pp.2336-2345, 2010. ,